Comparing single‐target and multitarget approaches for postoperative circulating tumour DNA detection in stage II–III colorectal cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13294
Abstract: Circulating tumour DNA (ctDNA) detection for postoperative risk stratification in cancer patients has great clinical potential. However, low ctDNA abundances complicates detection. Multitarget (MT) detection strategies have been developed to increase sensitivity. Yet, empirical evidence… read more here.
Keywords: tumour dna; circulating tumour; cancer patients; ctdna detection ... See more keywords
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical chemistry"
DOI: 10.1093/clinchem/hvac214
Abstract: BACKGROUND KRAS circulating tumor DNA (ctDNA) has shown biomarker potential for pancreatic ductal adenocarcinoma (PDAC) but has not been applied in clinical routine yet. We aim to improve clinical applicability of ctDNA detection in PDAC… read more here.
Keywords: kras ctdna; ctdna detection; detection; blood ... See more keywords
Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation: Interim results.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.552
Abstract: 552 Background: Over half of patients (pts) with oligometastatic CRC treated with definitive surgery or radiotherapy experience cancer recurrence. Early detection of ctDNA could identify high risk pts for additional intervention to eliminate micrometastatic disease.… read more here.
Keywords: post procedure; ctdna detection; procedure; recurrence ... See more keywords
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.17_suppl.lba507
Abstract: LBA507 Background: In monarchE (NCT03155997), 2 years of adjuvant abemaciclib + ET resulted in sustained improvement in invasive disease-free survival (IDFS; HR=0.680, 7.6% absolute benefit at 5 years) in patients (pts) with HR+, HER2-, node-positive,… read more here.
Keywords: therapy; ctdna detection; risk; monarche ... See more keywords
Impact of androgen deprivation therapy (ADT) on circulating tumor DNA (ctDNA) detection in de novo metastatic castration-sensitive prostate cancer (mCSPC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.204
Abstract: 204 Background: Plasma ctDNA is detected in most patients with metastatic castration-resistant prostate cancer, enabling minimally invasive tumor genotyping that informs prognosis and therapy decisions. However, most patients with de novo mCSPC will commence ADT… read more here.
Keywords: detection; novo mcspc; ctdna detection; adt ... See more keywords